Drug Database
DI

diptheria vaccine

✓ Approved

Serum Institute of India Pvt. Ltd. · Vaccine · Vaccine

What is diptheria vaccine?

diptheria vaccine is a vaccine developed by Serum Institute of India Pvt. Ltd.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

CompanySerum Institute of India Pvt. Ltd.
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Serum Institute of India Pvt. Ltd.

Therapeutic Indications

diptheria vaccine is developed for 4 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026-07-17

Artificial Intelligence Across the Vaccine Clinical Trial Lifecycle: Evidence, Readiness, and Guardrails.

Idriss Jad J, Kalash Suha S, Faraj Jana Abu JA, Nolan Lauren L et al.

Artificial intelligence (AI) is increasingly being used to support clinical research, but its value in vaccine clinical trials requires careful evidence-based assessment. Vaccine trials pose distinctive challenges, including high safety expectations in healthy participants, evolving pathogen exposure and baseline immunity, incomplete correlates of protection, applicability of findings to intended-use populations, and intense public scrutiny. We conducted a structured, vaccine-focused narrative review of AI applications across the vaccine trial lifecycle, supplemented by targeted clinical trial and vaccine pharmacovigilance studies with directly transferable methods. In the combined evidence base, evidence is strongest for operational uses, particularly recruitment, eligibility screening, trial matching, and risk-based monitoring. Applications to immune-response interpretation, correlates of protection, and vaccine safety surveillance are promising but remain less prospectively validated. Responsible adoption should be guided by intended tool use, evidence of strength, data governance, regulatory expectations, and preservation of human scientific and safety judgment.

PMID 42464875
Read full article →
PubMedIranian journal of nursing and midwifery research2026-07-17

Investigate the Relationship Between Receiving the COVID-19 Vaccine and Menstrual Disorders among Females of Reproductive Age in Jeddah, Saudi Arabia.

Esheaba Ola M OM, Fouly Howieda A HA, Kassem Fathia K FK

There are many physical side effects of the COVID-19 vaccine, including unexpected changes occurring in menstrual bleeding. This study aimed to assess the relation between the COVID-19 vaccine and disorders in menstruation among females of reproductive age. Participants were recruited from a nonprobability snowball sampling targeted at females who are living in Jeddah city between March 2022 and August 2022, Kingdom of Saudi Arabia (KSA). A quantitative cross-sectional design was utilized to conduct the study, a nonexperimental design based on a single observation point. The sample size is estimated by the G*Power software to be 180, considering missed cases, it increased to 197. Regarding menstrual changes, n = 86 (43.65%) experienced a delay, and about one-third reported an earlier menstruation cycle. A significant relationship is observed between nationality, occupation, and changes in period (t = 3.89, P < 0.001 and t = -2.94, P < 0.004). There is no significant difference in the occurrence of complications among the different vaccine types. Receiving the COVID-19 vaccine was strongly linked with unexpected disturbance in menstruation among the studied group, from simple menstrual irregulates to reported amenorrhea after receiving the booster doses. However, the occurrence of menstrual cycle delays was not linked to the vaccine type. Further studies should be done to investigate each type of vaccine specifically to determine if the type of vaccine affects the reproductive function generally not only the menstrual cycle, in a larger survey for more generalizability.

PMID 42466287
Read full article →
PubMedFrontiers in public health2026-07-17

Reframing vaccine narrative: a co-production study of a media campaign intervention to address childhood vaccine hesitancy among Nigerian parents and caregivers.

Ike Tarela Juliet TJ, Jidong Dung Ezekiel DE, Obi Callistar Kidochukwu CK, Ntaji Maureen Iru MI et al.

Childhood vaccine hesitancy is a public health concern. Nigeria is one of the countries with the highest rates of zero-dose childhood vaccination. This study makes an original contribution by adopting a co-production approach underpinned by interpretative phenomenological analysis (IPA) to meaningfully inform the co-production of a media campaign intervention with Nigerian parents/ caregivers whose child(ren) are not, or only partially, up to date with routine immunizations aimed at reducing childhood vaccine hesitancy and promoting uptake. A total of 10 parents or caregivers whose children were not up to date with their vaccinations were recruited for the study and participated in a focus group discussion. Data were analyzed using IPA. The findings reveal that hostility, misinformation, and the breakdown of trust in vaccines, alongside faith, tradition, and the lived logic of alternative protection, intersect to exacerbate hesitancy. The findings also reveal that clarity, reassurance, and empowerment in vaccine communication, underpinned by gendered voices, can build trust in vaccine messaging and encourage uptake. The study offers important insights for policymakers and public health communication strategies, underscoring the need for culturally appropriate media campaign interventions that address vaccine-related concerns and foster uptake.

PMID 42465634
Read full article →
PubMedVaccine2026-07-17

Protective immunity of lectin-adjuvanted intraperitoneal injection vaccine against Aeromonas veronii infection in Oreochromis niloticus.

Guha Ritam R, Wangkahart Eakapol E, Elumalai Preetham P

Disease outbreaks caused by Aeromonas veronii pose a significant threat to Nile tilapia (Oreochromis niloticus) aquaculture. Lectin-based adjuvants, such as concanavalin A (ConA), can potentially enhance vaccine efficacy by stimulating both innate and adaptive immunity. This study evaluated the immunoprotective potential of a ConA-adjuvanted, formalin-inactivated A. veronii vaccine administered intraperitoneally. Nile tilapia were vaccinated intraperitoneally with the inactivated A. veronii vaccine formulated with ConA. Safety was assessed by monitoring fish behavior and physiological responses. Innate immune activation was evaluated through lysozyme (LZM), myeloperoxidase (MPO), and superoxide dismutase (SOD) assays. Humoral response was measured via serum IgM levels. Gene expression in head kidney and spleen tissues was analyzed for TCR-β, IgM, MHC -II, CD4, and proinflammatory cytokines (IL-1β, IL-8). Protective efficacy was determined by challenging vaccinated fish with live A. veronii and calculating relative percent survival (RPS). The vaccine was safe, with no adverse effects observed. Vaccinated fish showed significant increases in LZM, MPO, and SOD activities, indicating enhanced innate immunity. Serum IgM levels peaked at 42 days post-vaccination, demonstrating robust humoral response. Gene expression analysis revealed upregulation of immune markers confirming activation of humoral (IgM), proinflammatory cytokine (IL-1β, IL-8) and cell-mediated pathways (TCR-β, MHC-II, CD4). Following challenge, the ConA-adjuvanted vaccine group exhibited the highest RPS (79%), significantly higher than controls. These results highlight the potent immunostimulatory effect of ConA and the vaccine's capacity to bridge innate and adaptive immunity in Nile tilapia. The adjuvant effects of ConA have improved the vaccine efficacy and immunogenicity.

PMID 42462678
Read full article →
PubMedScientific reports2026-07-17

Systems-level design of a multi-epitope immunotherapeutic vaccine targeting EBV-associated oncogenesis.

Charles Ssemuyiga S, Assumpta Naddamba N

Epstein-Barr virus (EBV) is an oncogenic herpesvirus associated with multiple lymphoid and epithelial malignancies. Despite extensive investigation of EBV vaccine strategies, effective therapeutic approaches capable of targeting established EBV-associated cancers remain limited. In this study, we developed an integrated immunoinformatics and structure-guided framework for the design and prioritization of therapeutic multi-epitope vaccine candidates targeting both structural glycoproteins (gp350, gB, gH/gL, and gp42) and latency-associated proteins (EBNA1, LMP1, LMP2, and BZLF1). Sixteen multi-epitope vaccine constructs were generated and evaluated through sequence validation, structural refinement, reverse vaccinology assessment, immune-response simulation, receptor interaction analysis, molecular dynamics simulations, and expression-readiness profiling. The prioritized epitope repertoire achieved projected global population coverage exceeding 98% for both MHC class I and II pathways. Structural refinement improved model quality across vaccine constructs, while immunological and safety assessments supported favorable predicted antigenicity, non-allergenic potential, non-toxicity, and developability properties. Immune simulations predicted coordinated innate, humoral, and cellular responses, with several constructs demonstrating strong predicted immunogenic profiles. Molecular docking and molecular dynamics analyses further supported predicted structural compatibility and interaction stability with immune-associated receptors under simulated conditions. Integrated multi-parameter evaluation identified Constructs 4, 7, 10, 8, and 12 as the most promising candidates, with Construct 4 exhibiting the most balanced profile across immunological, structural, safety, and expression-related properties. Collectively, this study provides a comprehensive computational framework for therapeutic EBV vaccine development and identifies prioritized vaccine candidates for experimental validation. The proposed strategy offers a scalable approach for accelerating the development of multi-epitope vaccines targeting persistent viral infections and virus-associated malignancies.

PMID 42463798
Read full article →
PubMedVaccine: X2026-07-17

Cross-country analysis on HPV vaccination behaviors among health workers and parents: a qualitative report from seven middle-income countries.

Almatkyzy Gulaiim G, Warsi Sahil Khan SK, Nielsen Siff Malue SM, Craig Brett J BJ

This article presents a cross-country analysis of qualitative research reports on the barriers and drivers of HPV vaccination-related behavior among parents and health workers in seven middle-income countries using the COM-B theoretical framework. Four reports are from countries that had already introduced the HPV vaccine - Georgia, Moldova, Turkmenistan, and Uzbekistan, while the other three reports are from Kazakhstan, Kosovo, and Tajikistan which were preparing for HPV vaccine introduction in 2023 and 2024. The cross-country analysis revealed that health workers (HWs), especially specialists like gynecologists and oncologists, were viewed as trusted sources of vaccination information by both parents and HWs. However, HWs faced gaps in HPV vaccine knowledge and communication skills, and these gaps persisted in some form even after training was conducted in countries that had already introduced the HPV vaccine. In addition, these specialists were not always included when training sessions were conducted with family doctors and nurses in preparation for the vaccine's introduction. Parents also experience knowledge gaps, safety concerns, and lack of trust. Parents across countries shared concerns related to HPV vaccine safety and effectiveness and were often exposed to misconceptions or misinformation through media and social networks. This was compounded by the lack of a strong and confident recommendation from HWs and poor patient-provider communication. The analyzed reports highlighted the need for tailored, multi-faceted interventions that account for locally specific issues, influencers, and target groups. Two prominent recommendations posited in the reports were: 1) engaging parents and addressing their concerns at the community level, and 2) ensuring HPV vaccine confidence through HW training and engagement, especially for specialists, and providing access to evidence-based information for HWs and others who influence vaccine acceptance.

PMID 42465981
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about diptheria vaccine